ArticleDiabetes2015

Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes.

Aixin Yu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.